Article

Dr. Susan Urba Discusses Cost Concerns for Treatment of Chemotherapy-Induced Nausea

In this segment, Dr. Susan Urba, University of Michigan, Comprehensive Cancer Center, talks about treatment guidelines and decisions relevant to chemotherapy-induced nausea and vomiting (CINV) in a managed care setting.

In addition, Dr. Urba warns of the consequences associated with the treatment of CINV when cost concerns impact best practices. Often, these consequences can include increased costs from uncontrolled symptoms and potential hospital admission due to dehydration.

Related Videos
Sarah Anderson, oncology strategy lead director, Novotech
Gladys Antelo-Allen
Jonathan Eisengart, MD
Chelsee Jensen, PharmD, BCPS.
Jonathan Eisengart, MD
Sarah Anderson, oncology strategy lead director, Novotech
Jonathan Eisengart
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo